Imaging urothelial bladder cancer: A VPAC PET targeted approach
Mathew L. Thakur1,2,3,4, Sushil K. Tripathi1, Leonard G. Gomella3,4, Ebru Salmanoglu5, Sung Kim1, William K. Kelly4,6, Scott W. Keith7, Charles Intenzo1, Peter McCue8, Jean Hoffman-Censits9, Edouard J. Trabulsi3,4
Canadian Journal of Urology, Vol.28, No.2, pp. 10596-10602, 2021
Abstract Introduction: Accurate staging of urothelial bladder cancer (UBC) with imaging, which guides effective bladder cancer treatment, remains challenging. This investigation is to validate a hypothesis that targeting vasoactive intestinal and pituitary adenylate cyclase activating peptide (VPAC) receptors using 64Cu-TP3805 can PET image UBC efficiently.
Materials and methods: Nineteen patients (aged 44-84 years) scheduled for radical cystectomy underwent VPAC positron emission tomography (PET) imaging prior to surgery. Sixteen had completed neoadjuvant chemotherapy before imaging. All 19 received 64Cu-TP3805 (148% ± 10% MBq) intravenously and were imaged 60 to 90 minutes later. Standard uptake value (SUV)max for malignant lesions and… More >